TickerFacts.

Caris Life Sciences, Inc. (CAI): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

$66.89M
Year ended 2025-12-31
$123.96M
Trailing 12 months to 2026-06-30
2023-12-31: -$298.42M2024-12-31: -$253.64M2025-12-31: $66.89M$66.89M
2023-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31$66.89Mn/m2026-03-03, From 2025-01-01
2024-12-31-$253.64Mn/m2026-03-03, From 2024-01-01
2023-12-31-$298.42Mn/a2026-03-03, From 2023-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Caris Life Sciences, Inc. (CAI)2025-12-31$66.89Mn/m
Guardant Health, Inc. (GH)2025-12-31-$233.07Mn/m
Veracyte, Inc. (VCYT)2025-12-31$126.63M+98.5%
Castle Biosciences Inc (CSTL)2025-12-31$28.33M-22.5%
Fulgent Genetics, Inc. (FLGT)2025-12-31-$124.21Mn/m
BillionToOne, Inc. (BLLN)2025-12-31$15.71Mn/m
Natera, Inc. (NTRA)2025-12-31$109.11M+57.6%
Fortrea Holdings Inc. (FTRE)2025-12-31$88.30M-62.8%
GRAIL, Inc. (GRAL)2025-12-31-$299.92Mn/m

Compare CAI, GH, VCYT, CSTL side by side · Screen every company in Services-Medical Laboratories ↗